| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXW4 |
| Uniprot No | P57775 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-412aa |
| 氨基酸序列 | MAAAAGEEEEEEEAARESAARPAAGPALWRLPEELLLLICSYLDMRALGRLAQVCRWLRRFTSCDLLWRRIARASLNSGFTRLGTDLMTSVPVKERVKVSQNWRLGRCREGILLKWRCSQMPWMQLEDDSLYISQANFILAYQFRPDGASLNRRPLGVFAGHDEDVCHFVLANSHIVSAGGDGKIGIHKIHSTFTVKYSAHEQEVNCVDCKGGIIVSGSRDRTAKVWPLASGRLGQCLHTIQTEDRVWSIAISPLLSSFVTGTACCGHFSPLRIWDLNSGQLMTHLGSDFPPGAGVLDVMYESPFTLLSCGYDTYVRYWDLRTSVRKCVMEWEEPHDSTLYCLQTDGNHLLATGSSYYGVVRLWDRRQRACLHAFPLTSTPLSSPVYCLRLTTKHLYAALSYNLHVLDFQNP |
| 预测分子量 | 62.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FBXW4重组蛋白的3篇参考文献示例(注：文献为模拟示例，实际引用需核实)：
1. **文献名称**：*Structural and functional characterization of recombinant FBXW4 in ubiquitin ligase complexes*
**作者**：Smith A, et al.
**摘要**：本研究通过在大肠杆菌中重组表达并纯化FBXW4蛋白，解析了其与Skp1-Cul1复合物的相互作用结构，揭示了FBXW4通过特定结构域识别底物的分子机制，为靶向泛素化通路的药物设计提供依据。
2. **文献名称**：*FBXW4重组蛋白的体外泛素化活性及其在结直肠癌中的功能研究*
**作者**：Li X, et al.
**摘要**：利用昆虫细胞系统表达重组人源FBXW4蛋白，证实其通过介导β-catenin的泛素化降解抑制结直肠癌细胞增殖，并发现特定突变体(R465C)导致功能丧失，与肿瘤进展相关。
3. **文献名称**：*Development of a high-yield FBXW4 recombinant protein production system in mammalian cells*
**作者**：Johnson R, et al.
**摘要**：优化哺乳动物细胞表达体系，实现FBXW4重组蛋白的高效分泌表达，验证其在体外结合Notch1并促进其降解的功能，为研究FBXW4在发育信号通路中的作用提供工具。
**提示**：实际研究中建议通过PubMed或Google Scholar搜索最新文献，结合关键词“FBXW4 recombinant protein”或“FBXW4 ubiquitin ligase”获取准确信息。
FBXW4 (F-box/WD repeat-containing protein 4) is a member of the F-box protein family, which functions as a substrate-recognition component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex. This complex plays a central role in the ubiquitin-proteasome system, tagging specific proteins with ubiquitin molecules for targeted degradation. FBXW4 is characterized by its F-box domain, enabling interaction with SKP1. and WD40 repeats that mediate substrate binding. It is implicated in regulating cellular processes such as cell cycle progression, signal transduction, and apoptosis by controlling the stability of key regulatory proteins.
Research on FBXW4 has linked it to several physiological and pathological contexts. For instance, it interacts with substrates like β-catenin and c-Myc, oncoproteins whose dysregulation is associated with cancer. FBXW4-mediated ubiquitination may suppress tumorigenesis by promoting the degradation of these oncogenic factors. However, its role appears context-dependent, as altered FBXW4 expression or mutations have been observed in cancers, neurodegenerative diseases, and developmental disorders, suggesting dual regulatory or pathogenic functions.
Recombinant FBXW4 protein, produced via heterologous expression systems (e.g., E. coli, mammalian cells), is widely used to study its biochemical interactions, structural properties, and enzymatic activity in vitro. Such studies help clarify its substrate specificity, post-translational modifications, and regulatory mechanisms. Additionally, recombinant FBXW4 serves as a tool for high-throughput drug screening to identify modulators of the ubiquitin-proteasome pathway, with therapeutic potential in diseases linked to protein stability defects. Ongoing research aims to dissect its precise biological roles and explore its utility as a biomarker or therapeutic target.
×
